This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
The validity of the primary studies was ensured by the selection of RCTs. Most of them were also double-blinded.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Three primary studies provided clinical data.
Methods of combining primary studies
The primary studies were not combined since data extracted from each RCT were used for a different analysis.
Investigation of differences between primary studies
Not relevant.
Results of the review
In the BAT study: the rate of death was 0.2% with bivalirudin and 0.2% with heparin, the rate of MI was 3.3% with bivalirudin and 4.2% with heparin, and the rate of MH was 3.5% with bivalirudin and 9.3% with heparin.
In the sub-group of patients who had experienced an MI in the BAT study: the rate of death was 0% with bivalirudin and 0.5% with heparin, the rate of MI was 3% with bivalirudin and 5.6% with heparin, and the rate of MH was 2.4% with bivalirudin and 11.8% with heparin Thus, the risk reduction for bleeding due to the use of bivalirudin was 9.4%. The sub-group analysis showed that the risk reduction for bleeding due to the use of bivalirudin was 6.7% in patients with renal impairment, 10.2% among women and 7.7% in elderly patients.
In the CACHET study: the rate of death was 0% with bivalirudin and 0% with heparin, the rate of MI was 2.1% with bivalirudin and 1.6% with heparin, and the rate of MH was 1.4% with bivalirudin and 6.3% with heparin.
In the REPLACE-1 study, the rates of death, MI and MH were, respectively: 
Measure of benefits used in the economic analysis
The summary benefit measure used was the rate of reduction in bleeding events. This was estimated directly from the effectiveness analysis and was used only in the sub-group analysis. The number-needed-to-treat (NNT) to prevent a bleeding episode was calculated only for the sub-group analysis.
Direct costs
The perspective adopted in the study was unclear, although it could have been that of the hospital. The health services included in the economic evaluation were cardiac catheterisation laboratory costs, non-procedural hospital costs, physician costs, complication costs and drug costs. The laboratory costs included procedures, disposable equipment, overheads, depreciation for the cardiac catheterisation laboratory, and non-physician personnel. The unit costs were presented separately from the quantities of resources used only for some cost items. The costs were estimated from the HCRI study, which considered a database of 3,271 procedures in which detailed resource use was collected on all patients, with costs determined by cost-accounting methods. The costs of complications were estimated using a multivariate analysis. Other costs were estimated from a Medicare cost report. Cost-to-charge ratios were also used to derive actual treatment costs. The drug costs came from average wholesale prices. The price year was not explicitly stated, but the costs were assessed in 2000 and 2001. Discounting was not relevant given the short timeframe of the analysis.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered in the economic evaluation.
Currency
US dollars ($).
Sensitivity analysis
Sensitivity analyses were not carried out.
Estimated benefits used in the economic analysis
The NNT to prevent a bleeding episode was 10.6 for patients with a recent MI, 15 among patients with renal impairment, 10 among women, and 13 for elderly patients. The reduction in bleeding events has been reported already.
Cost results
In the BAT study, the mean reduction in costs of complications per patient (including MI, transfusion costs and repeat PCI) was $636 with bivalirudin over heparin when considering the overall cohort, and $1,175 when only patients who had experienced MI were considered. The estimated cost of bivalirudin in this trial was $1,340.
